ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
- Conditions
- Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhotics
- Interventions
- Drug: ABT-493 coformulated with ABT-530
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 153
- Registration Number
- NCT02738138
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02725866
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
- Conditions
- Chronic Hepatitis C VirusHepatitis C Virus
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 136
- Registration Number
- NCT02723084
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 197
- Registration Number
- NCT02720523
- Locations
- 🇯🇵
Nagoya University Hospital /ID# 148005, Nagoya-shi, Aichi, Japan
🇯🇵Hamanomachi Hospital /ID# 147991, Fukuoka-shi, Fukuoka, Japan
🇯🇵Sapporo City General Hospital /ID# 147968, Sapporo, Japan
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT02719171
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
- Conditions
- Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 273
- Registration Number
- NCT02713295
- Locations
- 🇬🇷
PP of Ekaterini Galaterou /ID# 149713, Athens, AGIA Paraskeui, Greece
🇬🇷PP of Antonios Seretis /ID# 149714, Athens, Chalandri, Greece
🇬🇷PP of Maria Loukatou /ID# 149706, Athens, Glyfada, Greece
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
- Conditions
- Malignant MelanomaMedullary Thyroid CancerGlioblastomaLarge-Cell Neuroendocrine CarcinomaNeuroendocrine Prostate CancerHigh Grade Gastroenteropancreatic Neuroendocrine CarcinomaOther Neuroendocrine CarcinomaOther Solid Tumors
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT02709889
- Locations
- 🇺🇸
Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States
🇺🇸Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States
🇺🇸Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
- Conditions
- Chronic Hepatitis C VirusHepatitis C Virus
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 295
- Registration Number
- NCT02707952
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 648
- Registration Number
- NCT02706951
- Locations
- 🇺🇸
W. Broward Rheum Assoc Inc. /ID# 146010, Tamarac, Florida, United States
🇺🇸Sarasota Arthritis Center /ID# 146011, Sarasota, Florida, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 147175, Tucson, Arizona, United States
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1002
- Registration Number
- NCT02706873
- Locations
- 🇯🇵
Hokkaido University Hospital /ID# 148262, Sapporo, Japan
🇺🇸TriWest Research Associates- La Mesa /ID# 143738, La Mesa, California, United States
🇺🇸Desert Medical Advances /ID# 143730, Palm Desert, California, United States